INTRODUCTION

American tegumentary leishmaniasis (ATL) is a group of zoonotic diseases caused by around 12 species of the genus Leishmania. There are two main clinical forms of ATL: cutaneous (CL) and mucocutaneous/mucosal leishmaniasis (ML). Mucosal leishmaniasis is a complication of CL where metastasis to the mucosal tissues of the mouth and upper respiratory tract occurs by lymphatic or hematogenous dissemination. It is the most serious and destructive form of ATL. Mucosal leishmaniasis is caused mainly by Leishmania braziliensis; however, it is also observed in patients infected by Leishmania guyanensis, Leishmania panamensis, Leishmania amazonensis, and Leishmania peruviana, with most cases diagnosed in Bolivia, Brazil, and Peru. In Ecuador, parasitological confirmed cases of ML have been reported from the Amazon region and a few cases from the Pacific coast. In the Ecuadorian Amazon, the predominating species is L. braziliensis, whereas in the Pacific coast region it is L. guyanensis, as determined by DNA sequencing of cytochrome b (cyt b). Mucosal lesions can present after several months to 20 or more years after a primary CL lesion. However, about 15% of cases of ML give no previous history of CL. Nasal lesions are always present, with nodules and infiltration of the anterior cartilaginous septum; later, perforation of the septum occurs with collapse of the nose. The pharynx, palate, larynx, trachea, and upper lip can also be involved. In the final stage, there is severe mutilation, with destruction of the nose, pharynx, and larynx.

Mucosal leishmaniasis almost never heals spontaneously, and in general, treatment failures and relapses are common. The recommended treatment for ML by the WHO, Pan American Health Organization, and Ecuadorian Ministry of Public Health is the pentavalent antimonials. In Ecuador, meglumine antimoniate is available as Glucantime® (20 mg SbV/kg/day for 28 days by parenteral route, Aventis Sanofi-Pharma, Sao Paulo, Brazil). According to the PAHO expert committee (2013), miltefosine is an alternative option for the treatment of ML at a dosage of 1.5–2.5 mg/kg/day for 28 days, with a maximum dose of 150 mg/day. Miltefosine is an alkylphosphocholine analog originally developed as an antineoplastic agent. The U.S. Food and Drug Administration (reference ID: 3473277) has approved oral miltefosine (Impavido®–Knight Therapeutics, Montreal, Canada) for treatment of viscer al, CL, and mucosal leishmaniasis caused by some Leishmania species (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204684Orig1s000SumR.pdf). The drug efficacy varies according to the Leishmania species and the geographic location where the studies were performed. Adverse effects include vomiting, nausea, ketosis, headache, and transient elevation of creatinine and aminotransferase levels. At present, four studies have used miltefosine for ML, all in patients infected with L. Viannia subgenus, including L. guyanensis, L. braziliensis, and L. panamensis.

Herein, we report a case of an 88-year-old man diagnosed with severe and destructive ML caused by the species L. guyanensis and successfully cured by oral miltefosine.

CASE REPORT

On admission to the otorhinolaryngology service of a tertiary care hospital in Quito, an otherwise healthy 88-year-old mestizo man presented with nasal septal ulceration and extensive granulomatous lesions in the pharynx with accompanying dysphonia. The patient was born in Chunchi, a high Andean village. At 20 years of age, he moved to Cumanda, a subtropical area located in the Pacific coastal region of the province of Chimborazo. For the past 15 years, he had been residing in Quito. He had a 10-year history of nasal mucosal lesions that began with pruritus, nasal discharge, bleeding, crusts, and obstruction. It progressed to septal perforation, with granulomas in the pharynx and larynx producing dysphonia. Collapse of the nose occurred because of cartilage mutilation. He was clinically diagnosed with bacterial and fungal infections, receiving treatment with several classes of antibiotics (quinolones such as ciprofloxacin and macrolides such as clarithromycin) and itraconazole (200 mg/day for...
3 months). Because the ulceration persisted and progressed, he was treated with fluconazole (150 mg/day for 6 months) but without any improvement. Hence, he sought medical help at the Hospital in Quito. During the interview, he denied having traveled to the Amazon or any other leishmaniasis-endemic country.

On hospitalization, an otorhinolaryngological examination of the nasal and oral cavities showed nasal mucosal erythema, bleeding crusts, and destruction of the septum and turbinates (Figure 1A). Numerous nodules and granulomas were observed in the pharynx (Figure 2A). The patient did not have lymphadenopathy, hepatosplenomegaly, or fever. No active skin lesions or scars were observed over any part of the body.

All blood tests for white blood cells, red blood cells, hemoglobin, and platelet counts were within the normal range. ELISA for HIV, VDRL, hepatitis B surface antigen and fungal culture were all negative. Fasting blood glucose, blood urea nitrogen (BUN), and serum creatinine were 105, 15.5, and 1.93 mg/dL, respectively. Serum levels of both alanine amino-transferase and aspartate aminotransferase (AST) were normal before, during, and after treatment with miltefosine. The leishmanin skin test was performed by intradermal injection in the forearm, and an area of induration measured 15 mm 48 hours postinjection. Leishmanin solution was provided by PECET, Universidad de Antioquia, Medellin-Colombia (Cat.No. MSTA 90000, 5 mL).

Histopathology of a biopsy taken from the border of the ulcerative lesion on the nasal mucosa showed an inflammatory infiltrate, characterized by leukocytes, neutrophils, and lymphocytes, with scarce macrophages infected with few Leishmania spp. amastigotes. No malignant cells were observed. Staining for fungus and mycobacteria was negative. The tissue material was spotted onto an FTA Classic Card (Whatman, Newton Center, MA), and part of the spotted sample was used as a template for polymerase chain reaction (PCR). Leishmanial cyt b was amplified by PCR, and the cyt b gene sequence was subjected to a phylogenetic analysis. The analysis identified L. guyanensis as the causative agent (Figure 3).

The patient received ambulatory oral miltefosine 2.5 mg/kg/day (Impavido 50 mg capsules every 8 hours) for 28 days. Taking the medication with (fatty) food was recommended. Controls were carried out every week to record/evaluate any side effects and changes in the mucosal lesions. Nausea, loss of appetite, and epigastric pain were associated with the ingestion of miltefosine. Misoprostol (Cytotec® 800 ug every 8 hours, Piramal Healthcare United, United Kingdom) was prescribed to control the epigastric pain. Two months after treatment, the patient returned for a control and no active lesions were observed (Figures 1B and 2B). Three years later, the patient was healthy and no leishmaniasis reactivation was observed. A written consent signed by the patient’s sister was obtained to publish the case including the pictures of the lesions.

**DISCUSSION**

In the present case, oral miltefosine was shown to be effective in curing severe mucosal lesions caused by the New World L. guyanensis. In the four previous studies in which miltefosine was used to treat ATL ML, all showed good drug efficacy. Thus, studies in Bolivia showed a cure rate of 71%,14 but increasing the period of therapy from 4 weeks to 6 weeks, the cure rate increased to 75%.15 In Brazil, using oral miltefosine at 1.3–2 mg/kg/day for 28 days, 11/12 patients with ML were cured at 90 days after treatment, and on examination after 4 years, 16/18 patients were considered cured.16 In a pilot study in Argentina, seven of eight patients with ML were cured using a dose of 2.5–3.3 mg/kg/day.17

Not all Leishmania species are equally susceptible to miltefosine. There is a large natural variability of susceptibility to miltefosine among the various Leishmania species, as tested in vitro and in vivo.18–20 In the four prior clinical studies that were carried out, L. braziliensis was the predominant infecting species.14–17 In a systematic review published in 2013, at 6 months, a significant difference was noted in the rate of complete cure favoring miltefosine when compared with meglumine antimoniate for L. panamensis and L. guyanensis.13 In Ecuador, miltefosine has never been used to treat ML, and this is the first time to show here the efficacy of miltefosine in an infection due to L. guyanensis; in a case report of diffuse CL leishmaniasis caused by Leishmania mexicana, miltefosine failed to cure both clinically and parasitologically.21

The efficacy of miltefosine in ML is also dependent on the severity of the mucosal lesions. In Bolivia, for a “mild” ML disease (i.e., affecting nasal skin and nasal mucosa), a drug efficacy of 83% was attained, whereas in severe disease...
(involving the palate, pharynx, and larynx), it was only 58% effective. This corroborates a study we performed in Ecuador, but using itraconazole, a good response to treatment was associated with a short evolution of the disease and mild to moderate response in severe disease. Nevertheless, the present case was considered severe as shown in the figures before treatment with miltefosine.

Of interest, in this patient, *L. guyanensis* was identified as the causative species, which he probably contracted while living in the subtropical Pacific coast where *L. guyanensis* and *L. panamensis* are the dominant species. This region is considered endemic for CL, but where only a few as few cases of ML have been described. In Ecuador, *L. panamensis* and *L. guyanensis* are considered "benign" as they rarely metastasize to the mucosa. Moreover, our finding indicated that Ecuadorian *L. guyanensis* is capable of inducing ML as has been described in the neighboring countries of Colombia and Brazil. The localization of the mucosal lesions was similar to that reported elsewhere. Mucosal leishmaniasis cases detected in old patients are rare, but the present case was 88 years old; however, in a review of a retrospective study of 327 cases in Brazil, there was an increased risk above 60 years of age. In addition, there was a positive correlation between severity of mucosal disease and age.

The fact that the patient did not have active skin lesions or scars is in accordance with previous studies of individuals having ML, suggesting that a subclinical infection could occur. Furthermore, the ability of *Leishmania* parasites to remain latent during long periods and become active and invasive after (exogenous factors such as age) was demonstrated in the present case. Five years after leaving the leishmaniasis-endemic area, while living in Quito, the mucosal symptomatology began to appear which has continued to progress in the last 10 years.

The standard 28-day miltefosine monotherapy regimen was well tolerated, except for mild gastrointestinal side effects, as described in several other clinical studies. It is important to note that after the 3-year follow-up period, there was still no clinical evidence of relapse of the mucosal lesions, although previous studies have reported a high relapse rate of ML that tend to occur 1 year after completion of treatment. Miltefosine is not available in Ecuador, either in the public or in private sector, although in the CNMB 10th edition, it is considered as an alternative drug for leishmaniasis. There is a need for trials to compare safety and efficacy of miltefosine compared with antimonials in patients with ML in whom the infecting species of *Leishmania* have been identified.

Received November 23, 2019. Accepted for publication April 6, 2020. Published online June 8, 2020.

Acknowledgments: We thank Ivan Dario Velez from PECET, Universidad de Antioquia, Medellin-Colombia, for providing the Montenegro skin test antigen and miltefosine tablets. We thank Ronald Guderian for reviewing this case report.

Authors’ addresses: Manuel Calvopina and Sara Jijon, OneHealth Research Group, Carrera de Medicina, Facultad de Ciencias de La Salud, Universidad De Las Américas (UDLA), Quito, Ecuador, E-mails:
REFERENCES


